ENvue Medical Adds $1 Million Secured Financing, Cuts Series X Conversion Price to $0.50
ENvue Medical secured a $1M note from Alpha Capital, with $250K initially funded, to improve liquidity. The company also amended its Series X Preferred Stock terms, lowering the conversion price to $0.50 per share to support future financing, according to the company.
How this was made

The 30-second read
Why it matters
The new financing improves short‑term liquidity but is unlikely to move the stock significantly due to the modest size.
Market read
Primary corporate action for a micro‑cap biotech; limited broader market relevance.
What to watch
Potential future equity dilution from the preferred stock amendment.
Background
ENvue Medical disclosed a $1M secured promissory note and lowered the conversion price of its Series X preferred stock to $0.50.
Market effects
minimal impact on biotech financing trends
none
none
Counterpoint
The financing may signal cash constraints, but the low amount limits market reaction.
Key entities
- companyENvue Medical
Biotech firm issuing the financing and amendment.
- counterpartyAlpha Capital Anstalt
Provider of the secured promissory note.

